Invesco Exchange-Traded Fund Trust II has released its latest financial report, detailing significant assets under management. The report, filed on October 30, 2026, indicates that the fund's total assets amount to approximately $3.79 billion, with net assets reaching around $3.73 billion. This substantial financial position underscores Invesco's strength in the investment industry, particularly in the exchange-traded fund (ETF) sector.
The filing, identified by accession number 0001378872-26-001842, provides insights into the fund's performance and management strategies. With a focus on maintaining a competitive edge, Invesco continues to navigate the evolving landscape of investment management.
Background
Invesco Exchange-Traded Fund Trust II is a prominent player in the investment sector, specifically in the management of exchange-traded funds. The company is identified under the Central Index Key (CIK) 0001378872 and has undergone name changes in the past, previously known as PowerShares Exchange-Traded Fund Trust II. The fund is based in Downers Grove, Illinois, and operates under the SEC file number 811-21977.
What the Filing Says
The filing reveals that as of August 31, 2026, Invesco Preferred ETF, a key offering within the trust, holds total assets of approximately $3.79 billion. The report also indicates total liabilities of about $54.15 million, leading to net assets of approximately $3.73 billion. These figures reflect the fund's robust financial health and its ability to attract investor capital.
Impact
This report may affect investors and stakeholders interested in Invesco's performance and strategy within the competitive ETF market. The filing highlights the fund's ability to manage substantial assets, positioning it favorably against competitors like Morgan Stanley and Barclays, which are also active in the ETF space.
What's Next
The filing does not say what happens next, leaving stakeholders to anticipate future developments from Invesco Exchange-Traded Fund Trust II.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






